Skip to main content

Advertisement

SpringerLink
Log in

Hereditary renal cell carcinoma: genetics, clinical features, and surgical considerations

  • Topic Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Objectives

Hereditary renal cancer syndromes have been described and have illuminated novel methods to treat sporadic renal cell carcinoma. In this work, we aimed to review the genetic basis, molecular pathology and clinical manifestations of hereditary syndromes, as well as outline principles of surgical management and use of targeted therapy.

Methods

We performed a comprehensive review of selected peer-reviewed publications regarding hereditary renal cancer syndromes, their genetic basis, and recommendations for surgical management.

Results

The major syndromes contributing to hereditary renal cell carcinoma are discussed along with relevant literature guiding their management. The evolving surgical and molecular treatments are discussed.

Conclusions

Identification of genetic basis of hereditary carcinomas provides opportunity for targeted therapy of metastatic sporadic renal cell carcinoma.  Appropriate and timely surgical management of hereditary renal cancers decreases the possibility of development of metastatic disease, and allows for preservation of renal function despite the need for repeat surgical interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Howlader N, Noone AM, Krapcho M et al (2013) SEER cancer statistics review 1975–2010. National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/statfacts/html/kidrp.html. Accessed 24 Sept 2013

  2. Gudbjartsson T, Jonasdottir TJ, Thoroddsen A et al (2002) A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int J Cancer 100(4):476–479

    Article  CAS  PubMed  Google Scholar 

  3. Sorbellini M, Bratslavsky G (2012) Decreasing the indications for radical nephrectomy: a study of multifocal renal cell carcinoma. Front Oncol 2(84):1–5

    Google Scholar 

  4. Sato Y, Yoshizato T, Shiraishi Y et al (2013) Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45(8):860–869

    Article  CAS  PubMed  Google Scholar 

  5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C (2004) Chronic kidney disease and risk of death, cardiovascular events, and hospitalization. NEJM 351(13):1296–1305

    Article  CAS  PubMed  Google Scholar 

  6. Huang WC, Levey AS, Serio AM et al (2006) Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7:735–740

    Article  PubMed Central  PubMed  Google Scholar 

  7. Bratslavsky G, Liu JJ, Johnson AD, Sudarshan S, Choyke PL, Linehan WM, Pinto PA (2008) Salvage partial nephrectomy for hereditary renal cancer: feasibility and outcomes. J Urol 179:67–70

    Article  PubMed  Google Scholar 

  8. Neumann HP, Wiestler OD (1991) Clustering of features of Von Hippel–Lindau syndrome: evidence for a complex genetic locus. Lancet 337:1052

    Article  CAS  PubMed  Google Scholar 

  9. Neumann HP, Bender BU, Berger DP et al (1998) Prevalence, morphology, and biology of renal cell carcinoma in Von Hippel–Lindau disease compared with sporadic renal cell carcinoma. J Urol 160:1248–1254

    Article  CAS  PubMed  Google Scholar 

  10. Stolle C, Glenn GM, Zbar B et al (1998) Improved detection of germline mutations in the Von Hippel–Lindau disease tumor suppressor gene. Hum Mutat 12:417–423

    Article  CAS  PubMed  Google Scholar 

  11. Rosner I, Bratslavsky G, Pinto PA, Linehan WM (2009) The clinical implications of the genetics of renal cell carcinoma. Urol Oncol Semin 27:131–136

    Article  CAS  Google Scholar 

  12. Gallou C, Chauveau D, Richard S et al (2004) Geneotype–phenotype correlations in von Hippel–Lindau disease. Hum Mutat 24:215–224

    Article  CAS  PubMed  Google Scholar 

  13. Coleman JA, Russo P (2009) Hereditary and familial kidney cancer. Curr Opin Urol 19(5):478–485

    Article  PubMed  Google Scholar 

  14. Neumann HP, Zbar B (1997) Renal cysts, renal cancer, and von Hippel–Lindau disease. Kidney Int 51:16–26

    Article  CAS  PubMed  Google Scholar 

  15. Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, Oldfield EH (2003) Von Hippel Lindau disease. Lancet 361:2059–2067

    Article  CAS  PubMed  Google Scholar 

  16. Choyke PL, Filling-Katz MR, Shawker TH et al (1990) Von Hippel–Lindau disease: radiologic screening for visceral manifestations. Radiology 174((3 Pt 1)):815–820

    CAS  PubMed  Google Scholar 

  17. Duffey BG, Choyke PL, Glenn G, Grubb RL, Venzon D, Linehan WM, Walther MM (2004) The relationship between renal tumor size and metastases in patients with Von Hippel–Lindau Disease. J Urol 172:63–65

    Article  PubMed  Google Scholar 

  18. Gupta GN, Peterson J, Thakore KN, Pinto PA, Linehan WM, Bratslavsky G (2010) Oncologic outcomes of partial nephrectomy for multifocal renal cell carcinoma greater than 4 cm. J Urol 184(1):59–63

    Article  PubMed Central  PubMed  Google Scholar 

  19. Johnson A, Sudarshan S, Liu J, Linehan WM, Pinto PA, Bratslavsky G (2008) Feasibility and outcomes of repeat partial nephrectomy. J Urol 180:89–93

    Article  PubMed Central  PubMed  Google Scholar 

  20. Birt AR, Hogg GR, Dube WJ (1977) Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch Dermatol 113(12):1674–1677

    Article  CAS  PubMed  Google Scholar 

  21. Toro JR, Glenn G, Duray P et al (1999) Birt–Hogg–Dube syndrome: a novel marker of kidney neoplasia. Arch Dermatol 135(10):1195–1202

    Article  CAS  PubMed  Google Scholar 

  22. Schmidt LS, Nickerson ML, Warren MB et al (2005) Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt–Hogg–Dube syndrome. Am J Hum Genet 76:1023–1033

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Hong S, Oh H, Valera VA et al (2010) Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization. PLoS One 5(12):e15793

    Article  PubMed Central  PubMed  Google Scholar 

  24. Houweling AC, Gijezen LM, Jonker MA et al (2011) Renal cancer and pneumothorax risk in Birt–Hogg–Dube syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families. Br J Cancer 105:1912–1919

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Menko FH, van Steensel MA, Giraud S et al (2009) European BHD Consortium. Birt–Hogg–Dube syndrome: diagnosis and management. Lancet Oncol 10(12):1199–1206

    Article  CAS  PubMed  Google Scholar 

  26. Pavlovich CP, Walther MM, Eyler RA et al (2002) Renal tumors in the Birt–Hoog–Dube syndrome. Am J Surg Pathol 26(12):1542–1552

    Article  PubMed  Google Scholar 

  27. Boris RS, Benhammou J, Merino M, Pinto PA, Linehan WM, Bratslavsky G (2011) The impact of germline BHD mutation on histologic concordance and clinical management of patients with bilateral renal masses and known unilateral oncocytoma. J Urol 185(6):2050–2055

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Pavlovich CP, Grubb RL, Hurley K, Glenn GM, Toro J, Schmidt LS et al (2005) Evaluation and management of renal tumors in the Birt–Hogg–Dube syndrome. J Urol 173(5):1482–1486

    Article  PubMed  Google Scholar 

  29. Launonen V, Vierimaa O, Kiuru M et al (2002) Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Nat Acad Sci 98:3387–3392

    Article  Google Scholar 

  30. Tomlinson IP, Alam NA, Rowan AJ et al (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata, and papillary renal cell cancer. Nat Genet 30:406–410

    Article  CAS  PubMed  Google Scholar 

  31. Isaacs JS, Jung YJ, Mole DR et al (2005) HIF overexpression correlates with biallelic loss of fumaratehydratase in renal cell cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell 8:143–153

    Article  CAS  PubMed  Google Scholar 

  32. Toro JR, Nickerson ML, Wei MH et al (2003) Mutations in the fumaratehydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 73:95–106

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  33. Merino MJ, Torres-Cabala C, Pinto P, Linehan WM (2007) The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 31(10):1578–1585

    Article  PubMed  Google Scholar 

  34. Grubb RL, Franks ME, Toro J et al (2007) Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 177(6):2074–2079

    Article  CAS  PubMed  Google Scholar 

  35. Zbar B, Tory K, Merino M et al (1994) Hereditary papillary renal cell carcinoma. J Urol 151(3):561–566

    CAS  PubMed  Google Scholar 

  36. Schmidt L, Junker K, Weirich G et al (1998) Two North American families with hereditary papillary carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 58:1719–1722

    CAS  PubMed  Google Scholar 

  37. Linehan WM, Walther MM, Zbar B (2003) The genetic basis of cancer of the kidney. J Urol 170:2163–2172

    Article  CAS  PubMed  Google Scholar 

  38. Shuch B, Singer EA, Bratslavsky G (2012) The surgical approach to multifocal renal cancers: hereditary syndromes, ipsilateral multifocality, and bilateral tumors. Urol Clin N Am 39:133–148

    Article  Google Scholar 

  39. Herring JC, Enquist EG, Chernoff A et al (2001) Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10 year experience. J Urol 165:177

    Article  Google Scholar 

  40. Vanharanta S, Buchta M, McWhinney SR et al (2004) Early-onset renal cell carcinoma as a novel ex-traparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet 74:153

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Bardella C, Pollard PJ, Tomlinson I (2011) SDH mutations in cancer. Biochem Biophys Acta 1807:1342–1443

    Google Scholar 

  42. Ricketts CJ, Forman JR, Rattenberry E et al (2010) Tumor risks and genotype–phenotype–proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Hum Mutat 31:41–51

    Article  CAS  PubMed  Google Scholar 

  43. Ricketts CJ, Shuch B, Vocke CD et al (2012) Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol 188:2063–2071

    Article  CAS  PubMed  Google Scholar 

  44. Barrisford GW, Singer EA, Rosner IL, Linehan WM, Bratslavsky G (2011) Familial renal cancer: molecular genetics and surgical management. Int J Surg Oncol 6:658767

    Google Scholar 

  45. Cancer Genome Atlas Research Network (2013) Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499:43–49

    Article  Google Scholar 

  46. Carini M, Minervini A, Masieri L, Lapini A, Serni S (2006) Simple enucleation for the treatment of PT1a renal cell carcinoma: our 20-year experience. Eur Urol 50(6):1269–1271

    Article  Google Scholar 

  47. Minervini A, Ficarra V, Rocco F et al (2011) Simple enucleation is equivalent to traditional partial nephrectomy for renal cell carcinoma: results of a nonrandomized, retrospective, comparative study. J Urol 185(5):1604–1610

    Article  PubMed  Google Scholar 

  48. Kowalczyk KJ, Hooper HB, Linehan WM, Pinto PA, Wood BJ, Bratslavsky G (2009) Partial nephrectomy after previous radio frequency ablation: the National Cancer Institute experience. J Urol 182(5):2158–2163

    Article  PubMed Central  PubMed  Google Scholar 

  49. Singer EA, Gupta GN, Marchalik D, Srinivasan R (2013) Evolving therapeutic targets in renal cell carcinoma. Curr Opin Oncol 25(3):273–280

    CAS  PubMed  Google Scholar 

  50. Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ (2011) Targeted therapy for advanced renal cell carcinoma (RCC): a Cochrane systemic review of published randomized trials. BJU Int 108(10):1556–1563

    Article  CAS  PubMed  Google Scholar 

  51. Fishman MN (2013) Targeted therapy of kidney cancer: keeping the art around the algorithms. Cancer Control 20(3):222–232

    PubMed  Google Scholar 

  52. Escudier B, Gore M (2013) Sequencing therapy in metastatic renal cell cancer. Semin Oncol 40:465–471

    Article  CAS  PubMed  Google Scholar 

  53. Linehan WM (2012) Genetic basis of kidney cancer: role of genomics for the development of disease-based therapeutics. Genome Res 22:2089–2100

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no relevant conflicts of interest in this manuscript.

Author information

Authors and Affiliations

  1. Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA

    Timothy K. Byler & Gennady Bratslavsky

Authors
  1. Timothy K. Byler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gennady Bratslavsky
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gennady Bratslavsky.

Rights and permissions

Reprints and permissions

About this article

Cite this article

K. Byler, T., Bratslavsky, G. Hereditary renal cell carcinoma: genetics, clinical features, and surgical considerations. World J Urol 32, 623–630 (2014). https://doi.org/10.1007/s00345-014-1287-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-014-1287-4

Keywords

Search

Navigation